Joshua H. Bilenker, President & CEO at Loxo Oncology, Inc. (LOXO), sold 8,550 shares at $137.92 ($1.2M) on 2018-11-27, disclosed to the SEC on 2018-11-28.
Open-market sale of $1.2M LOXO by President & CEO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $137.92 | 2,329 | $321K | 26.8% |
| 2 | $138.94 | 2,638 | $367K | 30.6% |
| 3 | $140.14 | 700 | $98K | 8.2% |
| 4 | $141.48 | 690 | $98K | 8.1% |
| 5 | $142.45 | 634 | $90K | 7.5% |
| 6 | $143.35 | 859 |
| $123K |
| 10.3% |
| 7 | $144.61 | 700 | $101K | 8.4% |
| Total | $140.13 avg | 8,550 | $1.2M | 100% |
| Filing → |
| LOXO | SELL | 2018-12-12 | $2.7M | — | Filing → |
| LOXO | SELL | 2018-12-12 | $1.0M | — | Filing → |
| LOXO | SELL | 2018-11-28 | $877K | — | Filing → |